Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Head & Neck 1Gastrointestinal 1

Conditions

Epstein-Barr Virus Infections 6Sarcoma, Kaposi 4Lymphoproliferative Disorders 4Nasopharyngeal Carcinoma 3Glioblastoma 3Cytomegalovirus Infections 3Multi-centric Castleman's Disease 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Acquired Immunodeficiency Syndrome 2Stomach Neoplasms 1Solid Tumor, Adult 1Sarcoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Neoplasms 1Neoplasm Metastasis 1Multiple Acyl Coenzyme A Dehydrogenase Deficiency 1Macular dystrophy, corneal type 1 1Lymphoma, Extranodal NK-T-Cell 1Lymphadenopathy 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Hodgkin Disease 1Herpes Simplex 1Head and Neck Neoplasms 1HIV Infections 1Fatigue Syndrome, Chronic 1Fatigue 1EBV Lymphomas 1

Interventions

Cyclophosphamide 444Rituximab 401Etoposide 224Vincristine 215Doxorubicin 201Filgrastim 200Prednisone 176Cytarabine 159Radiotherapy 152fludarabine phosphate 147Methotrexate 137Peripheral Blood Stem Cell Transplantation 129Melphalan 127fludarabine 115Busulfan 99Dexamethasone 93Tacrolimus 75Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 71Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 62Cyclosporine 62Bendamustine Hydrochloride 62Lenalidomide 60Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lymphoma × Valganciclovir × Clear all
NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

University of California, San Diego

Phase 2 Withdrawn
GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

NCT00217503 2013-06-20

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
15 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡